Regenerex Pharma, Inc. reported a net loss of $2.53 million for the fiscal year ending March 31, 2025, a decrease from a loss of $3.54 million in the previous year. The company has not generated any revenue during this period, maintaining its status as a startup focused on developing advanced wound care products. Operating expenses totaled $1.83 million, down from $3.47 million in the prior year, primarily due to reduced research and development costs. The company’s cash position improved significantly, with cash and equivalents rising to $653,025 from $372 a year earlier, largely due to financing activities that provided $2.28 million.
In terms of strategic developments, Regenerex has made notable progress in expanding its market presence. The company is actively negotiating contracts with state Medicaid programs, which could yield annual revenues exceeding $100 million. Additionally, Regenerex has entered into an agreement to purchase technology platforms for $2.4 million, with a note payable due in August 2025. The company has also appointed Kenneth W. Perry as Chief Financial Officer, bringing 40 years of healthcare experience to the leadership team.
Operationally, Regenerex is focusing on enhancing its product offerings and market reach. The company has developed proprietary technologies aimed at addressing various wound care needs, including chronic and acute wounds. Regenerex is also pursuing international distribution opportunities in Asian and Middle Eastern markets, with a specific agreement in place for the UAE. The company’s workforce remains small, with a total of four key personnel, but it is actively seeking to recruit additional qualified staff to support its growth.
Despite these advancements, Regenerex faces significant challenges, including a lack of revenue history and ongoing financial losses. The company has acknowledged substantial doubt about its ability to continue as a going concern without raising additional capital. Management is currently seeking to secure $500,000 in funding to sustain operations until contracts begin to generate revenue. The company’s future success will depend on its ability to navigate these financial hurdles while executing its strategic initiatives effectively.
About REGENEREX PHARMA, INC.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.